ArticleJournal of gastroenterology and hepatology2023
Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.
David E Kleiner, Mauricio Lisker-Melman, Abdus S Wahed, Atul K Bhan, Michael A Nalesnik, Eun-Young K Choi, Kelsey K Leonard, Marc G Ghany, Raymond T Chung, Adrian M Di Bisceglie and 1 more
Article in Journal of gastroenterology and hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 7 institutions in 1 country.
David E KleinerLaboratory of Pathology, National Institutes of Health, Bethesda, Maryland, USA.
Mauricio Lisker-MelmanDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Abdus S WahedDepartment of Statistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.
Atul K BhanDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Michael A NalesnikDepartment of Pathology, University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, USA.
Eun-Young K ChoiDepartment of Pathology, University of Michigan - Michigan Medicine, Ann Arbor, Michigan, USA.
Kelsey K LeonardDepartment of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.
Marc G GhanyLiver Diseases Branch, NIDDK, Bethesda, Maryland, USA.
Raymond T ChungDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Adrian M Di BisceglieDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-6075-9305
Hepatitis B Research Network
Massachusetts General Hospital · USNational Institutes of Health · USUniversity of Pittsburgh · USSaint Louis University · USUniversity of Michigan · USUPMC Health System · USWashington University in St. Louis · US
Funding
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
Hepatitis B Research Network - Data Coordination CenterU01DK082864 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BELLE, STEVEN H. · 2008 to 2019
$25.3M
ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
Postmortem PathologyZICBC010685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLEINER, DAVID ERWIN · 2009 to 2025
$14.3M
Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
Hepatitis B Research Network (HBRN): Natural History and Treatment StudiesU01DK082944 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COOPER, STEWART, KHALILI, MANDANA · 2008 to 2019
$10.0M
Observation Study of Persons with Chronic Hepatitis B Virus infection in North AmericaU01DK082874 · NIDDK · UNIVERSITY HEALTH NETWORK · PI JANSSEN, HARRY · 2008 to 2019
aimStaining for hepatitis B viral antigens is often done in liver biopsies from patients with chronic hepatitis B, but its correlates with clinical phenotypes are not well described.
methodsBiopsies were collected from a large cohort of adults and children with chronic hepatitis B viral infection through the Hepatitis B Research Network. Immunohistochemical staining of sections was done for hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) and then centrally read by the pathology committee. The degree of liver injury and pattern of staining were then correlated with clinical characteristics, including the clinical phenotype of hepatitis B.
resultsBiopsies from 467 subjects were studied, including 46 from children. Immunostaining for HBsAg was positive in 417 (90%) with scattered hepatocyte staining being the most common pattern. HBsAg staining correlated best with serum levels of HBsAg and hepatitis B viral DNA; the absence of HBsAg staining was often a prelude to loss of HBsAg from serum. HBcAg staining was positive in 225 (49%), and, while cytoplasmic staining was more frequent than nuclear staining, both nuclear and cytoplasmic positivity were often seen in the same specimen. Staining for HBcAg correlated with both level of viremia and liver injury. No biopsies from inactive carriers had stainable HBcAg, while 91% of the biopsies from those with hepatitis B e antigen-positive chronic hepatitis B stained positively for HBcAg.
conclusionImmunostaining for hepatitis B viral antigens may yield helpful insights into liver disease pathogenesis but appears to add little to commonly used serological and biochemical blood tests.
Indexed as
Hepatitis BHepatitis B, ChronicDNA, ViralHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHumansLiverDNA, ViralHepatitis B Core AntigensHepatitis B Surface Antigenshepatitis B, clinicalhepatologyhepatology, hepatitis B, immunologyhepatology, hepatitis B, virology
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease. · full record | OpenQuestion